Clinical Trial Result Information

Title of Study:
POTENTE Study: A Study of Early Virological Response in Naive Patients With Chronic Hepatitis C, Genotype 2 or 3, Treated With PEGASYS (Peginterferon alfa-2a (40KD)) Plus Copegus (Ribavirin).

Fast Facts:
Protocol number:ML21543
Sponsor:Hoffmann-La Roche
Company division:Pharmaceutical
Product name:PEGASYS
Generic name:peginterferon alfa-2a (40KD)
Phase of development:IV
Therapeutic area, approved indication:Hepatitis C, Chronic
Date of report:To be Published

Clinical study summary:
This trial does not yet have clinical trial results posted on this website. All trial results will be posted within one year of approval or one year after trial completion, unless the release of information is restricted due to journal publication timing or pending regulatory filing. For further information on the timing of posting clinical trial results please consult the Roche policy for posting information on this website.


Click here for the protocol registry listing of this trial.


Back

This site is run by CenterWatch, a publishing company that focuses on the clinical Trial Listings industry. The information provided in this service is designed to help patients find clinical Trial Results that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these Trial Listings.

Trial Results updated: August 29, 2008 at 10:30:08 AM

Copyright © 1995 - 2008, CenterWatch
All Rights Reserved

This site was developed in association with Illumina Interactive, Boston, MA